As of November 6, 2026, Lexeo Therapeutics, Inc. is a publicly traded company (Nasdaq: LXEO); its largest reported holder is Balyasny Asset Management L.P., with 9.99% on Schedule 13G/A of August 14, 2026, then Affinity Asset Advisors, LLC (8.4%) (Schedule 13G/A, August 14, 2026).
Is this your company?
About to sign with, pay or invest in Lexeo Therapeutics, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Lexeo Therapeutics, Inc. a real, registered company?
- Lexeo Therapeutics, Inc. files with the SEC under CIK 1907108 (its SEC filings).
- Its shares are listed under the ticker LXEO on Nasdaq (SEC company record).
- business address in New York, New York, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Lexeo Therapeutics, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names JPMorgan Chase (filed 2026-10-13).
Who are Lexeo Therapeutics, Inc.'s owners and officers?
Lexeo Therapeutics, Inc.: business address in New York, New York; industry Biological Products, (No Diagnostic Substances) (Schedule 13G, 2026-10-13).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-10-13 | Jpmorgan Chase & Co. | 5.5% |
| Schedule 13G, 2026-08-14 | Orbimed Advisors LLC | 4.1% |
| Schedule 13G/A, 2026-08-14 | Paradigm Biocapital Advisors LP | 5.3% |
| Schedule 13G/A, 2026-08-14 | Balyasny Asset Management L.P. | 9.99% |
| Schedule 13G/A, 2026-08-13 | Affinity Asset Advisors, LLC | 8.4% |
| Schedule 13G, 2026-08-07 | State Street Corporation | 5.5% |
| Schedule 13G/A, 2026-05-15 | Balyasny Asset Management L.P. | 9.69% |
| Schedule 13G/A, 2026-05-15 | Paradigm Biocapital Advisors LP | 8.3% |
| Schedule 13G, 2026-04-13 | Suvretta Capital Management, LLC | 7.7% |
| Schedule 13G/A, 2026-03-27 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-02-17 | Kenneth Griffin | 7.4% |
| Schedule 13G/A, 2026-02-17 | Paradigm Biocapital Advisors LP | 6.5% |
Questions about who owns Lexeo Therapeutics, Inc.
Who owns Lexeo Therapeutics, Inc.?
On this page, 7 holders' latest ownership filings report 5% or more of Lexeo Therapeutics, Inc.: Balyasny Asset Management L.P. (9.99%, Schedule 13G/A, filed 2026-08-14), Affinity Asset Advisors, LLC (8.4%, Schedule 13G/A, filed 2026-08-13), Suvretta Capital Management, LLC (7.7%, Schedule 13G, filed 2026-04-13), Kenneth Griffin (7.4%, Schedule 13G/A, filed 2026-02-17) and Jpmorgan Chase & Co. (5.5%, Schedule 13G, filed 2026-10-13); 2 more are listed above.
Who are the largest shareholders of Lexeo Therapeutics, Inc.?
By the share each holder's latest filing reports, the largest holders of Lexeo Therapeutics, Inc. on this page are Balyasny Asset Management L.P. (9.99%), Affinity Asset Advisors, LLC (8.4%) and Suvretta Capital Management, LLC (7.7%).
When did Balyasny Asset Management L.P. buy into Lexeo Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Balyasny Asset Management L.P. on this page is the Schedule 13G/A, filed 2026-05-15, reporting 9.69%; its latest, Schedule 13G/A filed 2026-08-14, reports 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Lexeo Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Lexeo Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Lexeo Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Lexeo Therapeutics, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 376,778 shares (0.46% of shares outstanding) (Form 4, 2026-09-28).
- , the chief operating officer: 138,288 shares (0.17% of shares outstanding) (Form 4, 2026-09-28).
- , the chief financial officer: 92,907 shares (0.11% of shares outstanding) (Form 4, 2026-08-19).
- , the chief medical officer: 84,908 shares (0.10% of shares outstanding) (Form 4, 2026-09-28).
- , the chief medical officer: 72,646 shares (0.09% of shares outstanding) (Form 4, 2025-11-20).
Shares outstanding: 82,046,255 as of 2026-08-10, from the company's latest SEC cover page.
How much has Lexeo Therapeutics, Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: acquired Mantle Therapeutics Inc. (2026-09-29).
Keep reading
More on Lexeo Therapeutics, Inc. and the records around it.
Lexeo Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Acquisition Sep 2026
Companies that share a holder
- Longitude Capital Partners IV, LLC also filed stake reports on 2 other companies: ZENAS BIOPHARMA, INC. (Oct 2025), CG Oncology, Inc. (Sep 2025)
- Affinity Asset Advisors, LLC also filed stake reports on 13 other companies: Amanat Acquisition Corp. (Aug 2026), Avalo Therapeutics, Inc. (Aug 2026), Equillium Inc. (Aug 2026)
- Paradigm BioCapital Advisors LP also filed stake reports on 22 other companies: Obsidian Therapeutics, Inc. (Oct 2026), Spyre Therapeutics, Inc. (Oct 2026), Tyra Biosciences, Inc. (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/lexeo-therapeutics